BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BridgeBio Pharma wasn’t one of them. The 10 stocks that made the cut ...

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...